Literature DB >> 16856818

Timing of cord clamping revisited.

Tali Levy1, Isaac Blickstein.   

Abstract

Although cord cutting has been performed since the beginning of mankind, the timing and advantages of early versus delayed cord clamping are still controversial. Early cord clamping (within the first 30 s after birth) is usually justified for potential prevention of postpartum hemorrhage and for immediate treatment of the newborn, but at the same time, may increase Rh-sensitization. Delayed cord clamping is performed after a period of 30 s during which 'placental transfusion' of approximately 80 mL of blood occurs. This amount seems to protect the baby from childhood anemia without increasing hypervolemia-related risks. In preterm infants, delayed clamping appears to reduce the risk of intraventricular hemorrhage and the need for neonatal transfusion. Obtaining cord blood for future autologous transplantation of stem cells needs early clamping and seems to conflict with the infant's best interest. Although a tailored approach is required in the case of cord clamping, the balance of available data suggests that delayed cord clamping should be the method of choice.

Entities:  

Mesh:

Year:  2006        PMID: 16856818     DOI: 10.1515/JPM.2006.056

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  3 in total

1.  Evaluation of Introduction of a Delayed Cord Clamping Protocol for Premature Neonates in a High-Volume Maternity Center.

Authors:  Lilly Y Liu; Joe M Feinglass; Janine Y Khan; Susan E Gerber; William A Grobman; Lynn M Yee
Journal:  Obstet Gynecol       Date:  2017-05       Impact factor: 7.661

Review 2.  Anemia of prematurity: how low is too low?

Authors:  Catherine C Cibulskis; Akhil Maheshwari; Rakesh Rao; Amit M Mathur
Journal:  J Perinatol       Date:  2021-03-04       Impact factor: 3.225

Review 3.  Mankind's first natural stem cell transplant.

Authors:  Jose N Tolosa; Dong-Hyuk Park; David J Eve; Stephen K Klasko; Cesario V Borlongan; Paul R Sanberg
Journal:  J Cell Mol Med       Date:  2010-02-05       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.